Xu X, Hamhouyia F, Thomas S D, Burke T J, Girvan A C, McGregor W G, Trent J O, Miller D M, Bates P J
Human Molecular Biology Group, James Graham Brown Cancer Center, Department of Medicine, University of Louisville, Louisville, Kentucky 40202, USA.
J Biol Chem. 2001 Nov 16;276(46):43221-30. doi: 10.1074/jbc.M104446200. Epub 2001 Sep 12.
The discovery of G-rich oligonucleotides (GROs) that have non-antisense antiproliferative activity against a number of cancer cell lines has been recently described. This biological activity of GROs was found to be associated with their ability to form stable G-quartet-containing structures and their binding to a specific cellular protein, most likely nucleolin (Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., and Miller, D. M. (1999) J. Biol. Chem. 274, 26369-26377). In this report, we further investigate the novel mechanism of GRO activity by examining their effects on cell cycle progression and on nucleic acid and protein biosynthesis. Cell cycle analysis of several tumor cell lines showed that cells accumulate in S phase in response to treatment with an active GRO. Analysis of 5-bromodeoxyuridine incorporation by these cells indicated the absence of de novo DNA synthesis, suggesting an arrest of the cell cycle predominantly in S phase. At the same time point, RNA and protein synthesis were found to be ongoing, indicating that arrest of DNA replication is a primary event in GRO-mediated inhibition of proliferation. This specific blockade of DNA replication eventually resulted in altered cell morphology and induction of apoptosis. To characterize further GRO-mediated inhibition of DNA replication, we used an in vitro assay based on replication of SV40 DNA. GROs were found to be capable of inhibiting DNA replication in the in vitro assay, and this activity was correlated to their antiproliferative effects. Furthermore, the effect of GROs on DNA replication in this assay was related to their inhibition of SV40 large T antigen helicase activity. The data presented suggest that the antiproliferative activity of GROs is a direct result of their inhibition of DNA replication, which may result from modulation of a replicative helicase activity.
最近报道了富含鸟嘌呤的寡核苷酸(GROs)对多种癌细胞系具有非反义抗增殖活性的发现。已发现GROs的这种生物学活性与其形成稳定的含G-四联体结构的能力以及与一种特定细胞蛋白(很可能是核仁素)的结合有关(贝茨,P.J.,卡隆,J.B.,托马斯,S.D.,特伦特,J.O.,和米勒,D.M.(1999年)《生物化学杂志》274,26369 - 26377)。在本报告中,我们通过研究它们对细胞周期进程以及核酸和蛋白质生物合成的影响,进一步探究GROs活性的新机制。对几种肿瘤细胞系的细胞周期分析表明,在用活性GRO处理后,细胞在S期积累。对这些细胞中5-溴脱氧尿苷掺入的分析表明不存在从头DNA合成,这表明细胞周期主要在S期停滞。在同一时间点,发现RNA和蛋白质合成仍在进行,这表明DNA复制的停滞是GRO介导的增殖抑制中的主要事件。DNA复制的这种特异性阻断最终导致细胞形态改变和凋亡诱导。为了进一步表征GRO介导的DNA复制抑制,我们使用了基于SV40 DNA复制的体外测定法。发现GROs能够在体外测定中抑制DNA复制,并且这种活性与其抗增殖作用相关。此外,GROs在此测定中对DNA复制的影响与其对SV40大T抗原解旋酶活性的抑制有关。所呈现的数据表明,GROs的抗增殖活性是其抑制DNA复制的直接结果,这可能是由复制解旋酶活性的调节导致的。